Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.

Han Y, Lindner S, Bei Y, Garcia HD, Timme N, Althoff K, Odersky A, Schramm A, Lissat A, Künkele A, Deubzer HE, Eggert A, Schulte JH, Henssen AG.

Cancer Lett. 2019 Mar 31;445:24-33. doi: 10.1016/j.canlet.2018.12.012. Epub 2019 Jan 4.

PMID:
30611741
2.

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A.

Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840.

3.

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.

Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.

4.

Targeting tachykinin receptors in neuroblastoma.

Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schäfers S, De Preter K, Astrahanseff K, Struck J, Schramm A, Eggert A, Bergmann A, Schulte JH.

Oncotarget. 2017 Jan 3;8(1):430-443. doi: 10.18632/oncotarget.13440.

5.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH.

Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2.

6.

Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.

Lindner S, Bachmann HS, Odersky A, Schaefers S, Klein-Hitpass L, Hero B, Fischer M, Eggert A, Schramm A, Schulte JH.

Biomed Rep. 2015 Jul;3(4):443-446. Epub 2015 May 13.

7.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
8.

Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells.

Pajtler KW, Mahlow E, Odersky A, Lindner S, Stephan H, Bendix I, Eggert A, Schramm A, Schulte JH.

Oncotarget. 2014 Nov 30;5(22):11180-92.

9.

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.

Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, Epple M, Kozlova D, Yoon S, Baek K, Vandesompele J, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2015 Mar 15;136(6):1308-20. doi: 10.1002/ijc.29091. Epub 2014 Aug 5.

10.

Analysis of double-strand break repair by nonhomologous DNA end joining in cell-free extracts from mammalian cells.

Pfeiffer P, Odersky A, Goedecke W, Kuhfittig-Kulle S.

Methods Mol Biol. 2014;1105:565-85. doi: 10.1007/978-1-62703-739-6_39.

PMID:
24623253
11.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

12.

MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.

Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH.

Int J Cancer. 2013 Sep 1;133(5):1064-73. doi: 10.1002/ijc.28091. Epub 2013 Mar 7.

13.

Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.

Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH.

Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967.

14.

The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV.

Kuhfittig-Kulle S, Feldmann E, Odersky A, Kuliczkowska A, Goedecke W, Eggert A, Pfeiffer P.

Mutagenesis. 2007 May;22(3):217-33. Epub 2007 Mar 7.

PMID:
17347130
15.

Analysis of DNA double-strand break repair by nonhomologous end joining in cell-free extracts from mammalian cells.

Pfeiffer P, Feldmann E, Odersky A, Kuhfittig-Kulle S, Goedecke W.

Methods Mol Biol. 2005;291:351-71.

PMID:
15502235
16.

Repair of sequence-specific 125I-induced double-strand breaks by nonhomologous DNA end joining in mammalian cell-free extracts.

Odersky A, Panyutin IV, Panyutin IG, Schunck C, Feldmann E, Goedecke W, Neumann RD, Obe G, Pfeiffer P.

J Biol Chem. 2002 Apr 5;277(14):11756-64. Epub 2002 Jan 30.

Supplemental Content

Loading ...
Support Center